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Abstract 
Gestational diabetes (GDM) burden has been increasing progressively over the past years. Knowing that intrauterine 
exposure to maternal diabetes confers high risk for macrosomia as well as for future type 2 diabetes and obesity of the 
offspring, health care organizations try to provide effective control in spite of the limited resources. Artificial-intelligence-
augmented telemedicine has been proposed as a helpful tool to facilitate an efficient widespread medical assistance to GDM. 
The aim of the study we present was to test the feasibility and acceptance of a mobile decision-support system for GDM, 
developed in the seventh framework program MobiGuide Project, which includes computer-interpretable clinical practice 
guidelines, access to data from the electronic health record as well as from glucose, blood pressure, and activity sensors. 
The results of this pilot study with 20 patients showed that the system is feasible. Compliance of patients with blood glucose 
monitoring was higher than that observed in a historical group of 247 patients, similar in clinical characteristics, who had 
been followed up for the 3 years prior to the pilot study. A questionnaire on the use of the telemedicine system showed a 
high degree of acceptance. 
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Gestational diabetes (GDM) is classically defined as carbo-
hydrate intolerance that begins or is first recognized during 
pregnancy but in recent years the preferred definition has 
been modified trying to distinguish women with preexisting 
diabetes.1 GDM occurs when beta cell function is not suffi-
cient to overcome the insulin resistance produced by changes 
in diabetogenic hormones during pregnancy. Several adverse 
outcomes have been associated with GDM, including fetal 
macrosomia, birth trauma and perinatal complications. 
Importantly, the risk of these outcomes increases continu-
ously as maternal fasting plasma glucose levels increases.2 In 
2010, the International Association of Diabetes and 
Pregnancy Study Group (IADPSG), proposed criteria for 
GDM based on the results of the 75-g glucose tolerance test.3 
The thresholds represent the glucose values at which the 
odds of infant birth weight, cord C-peptide, and percentage 
body fat >90 percentile were 1.75 times the estimated odds 
of these outcomes. The implementation of IADPSG diagnos-
tic criteria in Spanish population would increase GDM prev-
alence from 11% to 36%,4 an unaffordable burden which 
needs rethinking the current GDM clinical protocol. 
Women with GDM should measure their blood glucose 
(BG) concentration at least four times daily (fasting and one 
hour after each meal) to detect hyperglycemia. Results are 
usually recorded in a glucose logbook, along with dietary 
information, allowing recognition of women who should 
begin insulin therapy to decrease the risk of macrosomia.5 
There is conflicting evidence as to whether ketonuria is asso-
ciated with an adverse impact on fetal cognitive develop-
ment but it is usually recommended to monitor fasting 
urinary ketones.6 
Telemedicine has been applied to pregnancies compli-
cated by diabetes with the main impact being a reduction in 
the number of outpatient clinical encounters.7 However, the 
lack of smart decision-support tools seems to be an obstacle 
for the general adoption of telemedicine systems in 
diabetes.8 Face-to-face visits usually take a well-predefined 
time slot. However, using more flexible telemedicine appli-
cations without automated decision support, data transmis-
sion confirmation, analyses, and feedback to patients may be 
even more time consuming. Mobile applications, which are 
well accepted by patients with diabetes, allow using auto-
matic processing tools to provide real-time advice based on 
BG monitoring. An example could be the automated confir-
mation that metabolic control parameters are maintained 
within normal levels, saving time to doctors and nurses. 
There is limited experience in artificial intelligence meth-
odologies applied to decision support for diabetes manage-
ment. Nevertheless, the huge amount of available data that 
potentially influence glucose behavior has caught the atten-
tion of computer engineers on diabetes. MobiGuide is a 
mobile telemedicine system that can be run in Android 
devices, based on computer interpretable guidelines (CIG) 
for giving personalized decision support to GDM patients, 
which can be delivered anytime everywhere. The MobiGuide 
Project is an EU-F7 funded project that has developed a 
patient guidance system integrating hospital and monitoring 
data into a personal health record (PHR) accessible by 
patients and care providers. In addition, the system supply 
personalized secure clinical-guideline-based guidance also 
outside clinical environments. Its ubiquity has been achieved 
by having a decision support system (DSS) at the back end, 
and on the front end by utilizing body area network (BAN) 
technology and developing a coordinated light-weight DSS. 
Methodology to extract patient-oriented knowledge from 
clinical practice guidelines is specified elsewhere.9 In brief, 
clinicians developed a consensus guideline which was for-
malized and then customization of the CIG was added to take 
into account patient context (eg, reduced number of BG mea-
surements during periods of semiroutine meal schedules). 
The consequent plan activation or notification affected 
patients and, when necessary, doctors. For example, when 
ketonuria value was introduced by the patient as positive, a 
question was asked of her: "Have you been eating your pre-
scribed amount of carbohydrates?" If the answer was "yes" 
and no previous notification had been sent before, then the 
notification to the patient was, "Ketonuria has been positive, 
please increase your carbohydrate bedtime by 10 grams." 
The designed pilot study was aimed at assessing the feasibil-
ity of the system and the advantages of monitoring blood 
glucose, ketonuria, diet, blood pressure, and physical activity 
in GDM patients. 
Patients and Methods 
Twenty patients diagnosed with GDM were included in this 
pilot study. Inclusion criteria were GDM diagnosed accord-
ing to National Diabetes Data Group criteria10 before 34th 
gestational week, age older than 18 years, familiarity with 
smartphones and computer technology in general, and will-
ingness to participate. We excluded the following categories 
of patients: diabetes diagnosed previously to the pregnancy 
(pregestational diabetes); hemoglobin Alc>6.5%; active 
treatment with drugs that could increase glycemia; blind-
ness; severe mental disturbances; inability to speak/under-
stand at least one of the following languages: Spanish, 
Catalan, or English; and frequent need to reside in remote 
areas without cellular network data coverage. The enrolled 
patients were given a monitoring system made by three 
components: (1) A smartphone device with 3G/4G data net-
work capability and a specifically designed software to col-
lect the clinical data and a messaging system (Figure 1), 
which included an accelerometer to detect the level of phys-
ical activity and an application that allowed one to manually 
introduce the results of fasting daily ketonuria determina-
tion (-/+/++); (2) a glycometer device with Bluetooth con-
nectivity (Accu-Chek Aviva Connect, Roche Diagnostics 
GmbH, Mannheim, Germany); and 3) a blood pressure (BP) 
monitor with Bluetooth connectivity (Bluetooth Blood 
Pressure Monitor 708-BT, Omron Healthcare Co, Ltd, 
Kyoto, Japan). At the moment of the enrollment the patients 
were trained on the app as well as the different devices. 
Personalization was achieved by considering patient prefer-
ences (eg, sending reminders at patient-specific meal times) 
and context. The patient data needed for the DSS was copied 
from the hospital electronic medical record (EMR) (Hewlett 
Packard Healthcare Information System, Hewlett-Packard 
Development Company, L.P., Madrid, Spain ) into the PHR 
at the moment of enrollment and periodically refreshed to 
keep it up to date. HL7's virtual medical record standard 
was used as the data model of the PHR.11 
Patients were asked to download BG values (fasting and 
1-hour postprandial) from the glycometer every 3 days as 
well as to inform on ketonuria status and diet compliance. 
Patients were also required to measure BP twice a week and 
advised to use the developed app to monitor physical activity 
episodes. Compliance was measured as the ratio "number of 
measurements downloaded'V'number of measurements 
expected." During the study period patients were asked to 
follow their face-to-face visits with the nurse or doctor as 
usual. Health care providers involved in the study (doctors, 
nurses) used a web-based application to visualize all the 
patient data (EMR) including monitoring data, messages, 
and so on. 
Patients satisfaction was evaluated using an ad-hoc ques-
tionnaire that patients filled in at the end of the study. Each 
question was answered with a 5 point semantic differential 
scale (the higher the better). 
During the technical development of the MobiGuide sys-
tem (2012-2014), we performed in parallel an observational 
prospective study to capture the main relevant clinical data 
for describing our usual population of GDM patients with 
respect to basal conditions, metabolic outcomes, delivery-
related variables and neonatal complications. 
Both studies (pilot study and the observational prospec-
tive GDM cohort study) were approved by the local ethics 
committee and patients signed the informed consent. 
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Figure I. MobiGuide user interface examples, (a) Home screen, (b) Physical activity, (c) Advice delivered to the patient: survey for diet 
compliance because of hyperglycemia. 
Table I. Comparison of Main Characteristics for the Intervention Group and the Historical Cohort. 
Intervention group Cohort P value 
Age (years) 
Pregestational weight (kg) 
Pregestational BMI (kg/m2) 
Gestational week at first visit 
Follow-up duration (days) 
week) 
35.2 ± 3.9 
69.8 ± 13.1 
25.7 ± 4.3 
30.7(27.5-32.1) 
54.5 (44.0-69.5) 
34.0 ± 4.5 
69.2 ± 14.0 
26.7 ± 5.7 
31.0 (29.0-33.0) 
55.5 (36.0-76.0) 
NS 
NS 
NS 
NS 
NS 
Values are mean ± SD or median (25th percentile - 75th percentile). NS, nonsignificant. 
The statistical analysis was performed using SPSS soft-
ware (IBM Software, version 23). Values are shown as mean 
± standard deviation for normally distributed variables and 
median (interquartile range) for the ones nonnormally dis-
tributed. We used i-test or Mann-Whitney U test for mean 
comparison of numerical variables and chi-square for cate-
gorical data. 
Results 
All the patients completed the study except for one who 
moved to other region. The data set contains a total of 4561 
BG measurements, 997 ketonuria values, 369 BP measure-
ments, and 184 exercise bouts. Main clinical characteristics 
are shown in Table 1 and compared with those corresponding 
with the historical cohort. In brief, patients enrolled in the 
pilot study seem to be representative of the usual patients 
referred because of GDM diagnosis. 
Table 2. Metabolic Outcomes for Patients in the Intervention 
Group Compared With Those Observed in the GDM Historical 
Cohort. 
BG (mg/dl) 
Systolic BP (mmHG) 
Diastolic BP (mmHG) 
BG > 140 mg/dl (%) 
Insulin therapy (%) 
Intervention group 
I I4 .3± 7.6 
99.9 ± 10.5 
62.4 ± 8.6 
14.2 ± 9.5 
52.6 
Cohort 
1 1 1.6 ± 8.7 
I I9.3± 12 
72.8 ± 9 
12.9 ± 10 
53.8 
P value 
NS 
<.00l 
<.00l 
NS 
NS 
Values are mean ± SD, unless otherwise noted. NS, nonsignificant. 
Tables 2 and 3 show the comparison of the metabolic and 
perinatal outcomes between telemedicine users and the his-
torical cohort. The only differences observed between groups 
were systolic and diastolic BP, which were lower in the inter-
vention group. 
T a b l e 3. Comparison of Perinatal Outcomes Between the Group of Women W h o Used Smart Telemedicine System and the Historical 
Cohort. 
Gestational week at delivery (week) 
Method of delivery (Cesarean section/operative/ 
spontaneous) (%) 
Birth weight (g) 
Newborn percentile 
Newborn large for gestational age (%) 
Intervention group 
39.3 (38.4-40.3) 
10.5/3 1.6/57.9 
3102 ±408 
42.1 ±28.1 
0 
Cohort 
39.0 (38.0-40.0) 
25.1/15.2/59.7 
3233 ± 433 
50.8 ± 29.0 
8.9 
P value 
NS 
NS 
NS 
NS 
NS 
Values are mean ± SD o r median (25th percentile - 75 th percentile), unless otherwise noted. NS, nonsignificant. 
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Figure 2 . Results of the participants end-of-study questionnaire 
(5 = strongly agree). 
Patients in the study downloaded BG data every 2.97 ± 
1.6 days and showed a higher degree of compliance (1.01 ± 
0.1 vs 0.87 ± 0.3, P < .05) than that observed in the historical 
cohort. BP data was downloaded every 7.6 ± 5.9 days and 
mean compliance with respect to BP measurements was 0.81 
± 0.2. Ketonuria status was informed every 3.2 ± 1.7 days, 
and mean patients compliance with ketonuria determination 
was 0.98 ± 0.04. Patients attended the diabetes and preg-
nancy clinic a median of 6 (5-7) times. 
All the patients received at least one message asking about 
diet compliance because of hyperglycemia and 6 patients 
were also asked because of ketonuria. Seven patients were 
advised to contact the doctor because of persistence of the 
metabolic problem despite of prescribed diet change when 
appropriate. In 16 patients the system automatically reduced 
the recommended frequency of BP/ketonuria monitoring 
because of persistent normal values and high compliance. 
Figure 2 show the results of the participants end-of-study 
questionnaire, mirroring a high degree of patients satisfac-
tion with the system. 
Discussion 
Our study results indicate that the developed smart telemedi-
cine system is a feasible and well-accepted mobile DSS for 
guiding GDM. Furthermore, compliance with BG monitor-
ing performance was clearly higher than that observed with 
usual care. Our interpretation is that immediate data analysis 
and feedback engage patients on performing BG measure-
ments. In addition, compliance with BP regular measurement 
was very high considering our group of normotensive preg-
nant women. Another important contribution of the system 
was the automated plan of diet adjustments to correct either 
hyperglycemia or ketonuria. CIGs are usually applied to help 
professionals to make better decisions. Our smart telemedi-
cine patient guidance system, helps patients through advice 
in accordance with the specific clinical guideline. 
Metabolic and perinatal outcomes were similar to those 
results showed in our cohort of GDM patients except for BP, 
which was lower in the intervention group. The most plausi-
ble explanation is that BP in patients using telemedicine was 
measured at home, and probably for this reason the mean 
values were lower than those observed in the cohort of GDM 
patients. 
A few randomized control trials have addressed the effect 
of telemedicine interventions on GDM management.12"16 
Very recently, a metanalysis found a mild but significant 
effect of telemedicine solutions on HbAlc in comparison 
with usual practice (5.22 ± 0.7 % vs 5.37 ± 0.6; mean differ-
ence -0.14% [95% CI -0.25, -0.04%]).17 Another previous 
metanalysis found fewer unscheduled visits while maintain-
ing quality of life, BG levels and rate of cesarean section.7 
Telemedicine interventions applied to GDM were based on 
data transmission with or without reminders but in all cases 
required expert analysis for giving asynchronous feedback to 
patients. The developed smart mobile telemedicine system is 
a new and unique system: incorporates CIG, integrates sen-
sors, retrieves key data from the EMR, takes into account 
personal context variables, and proposes diet changes with-
out medical supervision to correct hyperglycemia and/or 
ketonuria. 
Our study has some limitations. The study group was 
small, and no control group was included. However, a com-
parison with a wide cohort group was made to evaluate the 
telemedicine system in terms of safety and efficacy. Hardware 
was available to all the patients, and no limitations were 
imposed. However, a few patients were excluded because of 
limited technical skills. In consequence, even though the 
telemedicine system tested a very user-friendly application, 
in real life there may be limitations for this reason. 
Conclusions 
GDM is the most prevalent metabolic alteration diagnosed 
during pregnancy. As BG levels tend to increase week after 
week, weekly face-to-face visits are the current recom-
mended protocol, producing a huge burden for health care 
providers. Artificial-intelligence-augmented telemedicine 
can offer a good alternative, saving resources while main-
taining the standards of care proposed in the clinical 
guidelines. 
The data presented in this pilot study show the feasibility 
and acceptance of the developed smart telemedicine system 
DSS, a mobile application that includes CIG, access to data 
from the EMR, as well as access to data downloaded from 
the glycometer, BP monitor, and activity sensors. Patients' 
compliance with BG tests, the key parameter for GDM mon-
itoring, seems to benefit from the immediate analysis and 
feedback. The next step would be a comparison of the usual 
care with the use of this new telemedicine system in a ran-
domized controlled trial. 
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BAN, body area network; BG, blood glucose; BP, blood pressure; 
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